Protease inhibitors: drug resistance and cross resistance overview.

Abstract excerpt

Viral resistance to protease inhibitors, particularly saquinavir, is a problem. The background of this resistance, what is known about it, and questions concerning saquinavir dosage and formulation are discussed. The current dosage regimen, approved by the Food and Drug Administration (FDA), for saquinavir is too low. Drug trials with a new formulation are starting which will determine optimum dose levels, but...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Resistance, Microbial
• Share to HIV
• Share to HIV Protease Inhibitors